share_log

Sanofi | 6-K: Sanofi Announces Agreement for Potential First-in-Class Vaccine Against Extraintestinal Pathogenic E. Coli and Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

賽諾菲安萬特 | 6-K:賽諾菲安萬特宣布就潛在的第一類抗腸道外致病性大腸桿菌疫苗達成協議及賽諾菲安萬特和梯瓦宣布獨家合作提供炎癥性腸病治療藥物

美股SEC公告 ·  2023/10/11 06:05
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息